These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 30055890)
1. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. Imano H; Kato R; Tanikawa S; Yoshimura F; Nomura A; Ijiri Y; Yamaguchi T; Izumi Y; Yoshiyama M; Hayashi T J Pharmacol Sci; 2018 Jul; 137(3):274-282. PubMed ID: 30055890 [TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban Attenuates Right Ventricular Remodeling in Rats with Pulmonary Arterial Hypertension. Imano H; Kato R; Nomura A; Tamura M; Yamaguchi Y; Ijiri Y; Wu H; Nakano T; Okada Y; Yamaguchi T; Izumi Y; Yoshiyama M; Asahi M; Hayashi T Biol Pharm Bull; 2021 May; 44(5):669-677. PubMed ID: 33612567 [TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice. Narita M; Hanada K; Kawamura Y; Ichikawa H; Sakai S; Yokono Y; Senoo M; Narita N; Shimada M; Osanai T; Okumura K; Tomita H Hypertens Res; 2021 Oct; 44(10):1261-1273. PubMed ID: 34285375 [TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban Inhibits Angiotensin II-Induced Activation in Cultured Mouse Cardiac Fibroblasts Through the Modulation of NF-κB Pathway. Hashikata T; Yamaoka-Tojo M; Namba S; Kitasato L; Kameda R; Murakami M; Niwano H; Shimohama T; Tojo T; Ako J Int Heart J; 2015; 56(5):544-50. PubMed ID: 26370374 [TBL] [Abstract][Full Text] [Related]
5. Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation. Kondo H; Abe I; Fukui A; Saito S; Miyoshi M; Aoki K; Shinohara T; Teshima Y; Yufu K; Takahashi N J Cardiol; 2018 Mar; 71(3):310-319. PubMed ID: 28993090 [TBL] [Abstract][Full Text] [Related]
6. [Proteinase-activated Receptor 1 and 2 under Hypoxic Stress]. Hayashi T Yakugaku Zasshi; 2021; 141(10):1195-1204. PubMed ID: 34602516 [TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways. Zhang Q; Zhang Z; Chen W; Zheng H; Si D; Zhang W PeerJ; 2023; 11():e16097. PubMed ID: 37786576 [TBL] [Abstract][Full Text] [Related]
8. Prolyl 4-Hydroxylase Domain Protein 3 Overexpression Improved Obstructive Sleep Apnea-Induced Cardiac Perivascular Fibrosis Partially by Suppressing Endothelial-to-Mesenchymal Transition. Zhang GH; Yu FC; Li Y; Wei Q; Song SS; Zhou FP; Tong JY J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051216 [TBL] [Abstract][Full Text] [Related]
9. Pitavastatin reduces oxidative stress and attenuates intermittent hypoxia-induced left ventricular remodeling in lean mice. Inamoto S; Yoshioka T; Yamashita C; Miyamura M; Mori T; Ukimura A; Matsumoto C; Matsumura Y; Kitaura Y; Hayashi T Hypertens Res; 2010 Jun; 33(6):579-86. PubMed ID: 20300107 [TBL] [Abstract][Full Text] [Related]
10. Inhalation of hydrogen gas attenuates left ventricular remodeling induced by intermittent hypoxia in mice. Hayashi T; Yoshioka T; Hasegawa K; Miyamura M; Mori T; Ukimura A; Matsumura Y; Ishizaka N Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H1062-9. PubMed ID: 21642501 [TBL] [Abstract][Full Text] [Related]
11. Augmented O-GlcNAcylation attenuates intermittent hypoxia-induced cardiac remodeling through the suppression of NFAT and NF-κB activities in mice. Nakagawa T; Furukawa Y; Hayashi T; Nomura A; Yokoe S; Moriwaki K; Kato R; Ijiri Y; Yamaguchi T; Izumi Y; Yoshiyama M; Asahi M Hypertens Res; 2019 Dec; 42(12):1858-1871. PubMed ID: 31409917 [TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease-Activated Receptor Pathway. Ichikawa H; Shimada M; Narita M; Narita I; Kimura Y; Tanaka M; Osanai T; Okumura K; Tomita H J Am Heart Assoc; 2019 Apr; 8(8):e012195. PubMed ID: 30957622 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Yamashita C; Hayashi T; Mori T; Tazawa N; Kwak CJ; Nakano D; Sohmiya K; Okada Y; Kitaura Y; Matsumura Y Hypertens Res; 2007 Dec; 30(12):1219-30. PubMed ID: 18344628 [TBL] [Abstract][Full Text] [Related]
14. Capillary Degeneration and Right Ventricular Remodeling Due to Hypoxic Stress with Sugen5416. Woo E; Kato R; Imano H; Fujiwara Y; Ijiri Y; Okada Y; Yamaguchi T; Izumi Y; Yoshiyama M; Katsumata T; Hayashi T Curr Vasc Pharmacol; 2017; 15(6):589-598. PubMed ID: 28460626 [TBL] [Abstract][Full Text] [Related]
15. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice. Wang AW; Song L; Miao J; Wang HX; Tian C; Jiang X; Han QY; Yu L; Liu Y; Du J; Xia YL; Li HH Am J Hypertens; 2015 Apr; 28(4):518-26. PubMed ID: 25362112 [TBL] [Abstract][Full Text] [Related]
16. Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis. Chung CC; Lin YK; Chen YC; Kao YH; Yeh YH; Chen YJ J Mol Cell Cardiol; 2018 Oct; 123():128-138. PubMed ID: 30213724 [TBL] [Abstract][Full Text] [Related]
17. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways. Kang HH; Kim IK; Lee HI; Joo H; Lim JU; Lee J; Lee SH; Moon HS Biochem Biophys Res Commun; 2017 Aug; 490(2):349-355. PubMed ID: 28623125 [TBL] [Abstract][Full Text] [Related]
18. Celiprolol reduces oxidative stress and attenuates left ventricular remodeling induced by hypoxic stress in mice. Nishioka S; Yoshioka T; Nomura A; Kato R; Miyamura M; Okada Y; Ishizaka N; Matsumura Y; Hayashi T Hypertens Res; 2013 Nov; 36(11):934-9. PubMed ID: 23784509 [TBL] [Abstract][Full Text] [Related]
19. Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2-ERK 1/2 pathway. Maeda K; Kuriyama N; Noguchi D; Ito T; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Murata Y; Tanemura A; Kishiwada M; Mizuno S PLoS One; 2024; 19(5):e0292628. PubMed ID: 38748746 [TBL] [Abstract][Full Text] [Related]